下一代癌症诊断市场规模、份额、成长分析、按产品/服务、按技术、按癌症类型、按应用、按最终用途、按地区 - 2025 年至 2032 年行业预测

下一代癌症诊断市场预计将在 2023 年达到 159 亿美元，从 2024 年的 188.4 亿美元增长到 2032 年的 732.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 18.5%。

随着先进诊断仪器、套件和试剂的商业化，市场正从传统的实验室检测转变为快速就地检验。这种演变，特别是伴随诊断的兴起为个人化基因组医学提供了宝贵的机会，大大推动了市场的成长。近年来，全球范围内报告的非何杰金氏淋巴瘤和其他常见癌症病例超过 544,000 例，这说明全球癌症发生率不断上升，这凸显了对这些创新诊断工具的需求。癌症是全球第二大死因，每年造成超过 960 万人死亡。因此，下一代诊断技术的开发正在提高准确性和可负担性，促进更早的检测并在充满挑战的全球医疗保健领域改善患者的治疗效果。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

下一代癌症诊断市场规模（按产品/服务及复合年增长率） (2025-2032)

• 市场概览
• 产品
  • 装置
  • 套件和耗材
• 服务

下一代癌症诊断市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 下一代定序（NGS）
• 聚合酵素链锁反应（PCR）
• DNA微阵列
• 多路復用
• 其他的

下一代癌症诊断市场规模（按癌症类型和复合年增长率） (2025-2032)

• 市场概览
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 子宫颈癌
• 肝癌
• 其他癌症

下一代癌症诊断市场规模（按应用和复合年增长率） (2025-2032)

• 市场概览
• 筛检和早期检测
• 预测和监测
• 治疗方法方案
• 復发监测
• 其他的

下一代癌症诊断市场规模（按最终用途和复合年增长率） (2025-2032)

• 市场概览
• 医院和诊所
• 诊断实验室
• 学术研究所
• 其他的

下一代癌症诊断市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • 罗氏控股公司（瑞士）
    • 赛默飞世尔科技公司（美国）
    • Illumina公司（美国）
    • 雅培实验室（美国）
    • QIAGEN NV（Germany/Netherlands）
    • 安捷伦科技公司（美国）
    • Bio-Rad Laboratories, Inc.（美国）
    • 碧迪公司（BD）（美国）
    • Myriad Genetics, Inc.（美国）
    • Guardant Health, Inc.（美国）
    • 精确科学公司（美国）
    • 丹纳赫公司（美国）
    • 西门子医疗股份公司（德国）
    • Hologic公司（美国）
    • GE医疗（美国）
    • 诺华公司（瑞士）
    • 默克集团（德国）
    • Sysmex株式会社（日本）
    • Invitae公司（美国）

结论和建议

Next Generation Cancer Diagnostics Market size was valued at USD 15.9 billion in 2023 and is poised to grow from USD 18.84 billion in 2024 to USD 73.26 billion by 2032, growing at a CAGR of 18.5% during the forecast period (2025-2032).

The market is transitioning from traditional laboratory testing to rapid point-of-care testing, driven by the commercialization of advanced diagnostic devices, kits, and reagents. This evolution is significantly boosting market growth, particularly with the rise of companion diagnostics, which present valuable opportunities in personalized genomic medicine. The increasing global cancer prevalence underscores the demand for these innovative diagnostic tools, as evidenced by over 544,000 cases of non-Hodgkin lymphoma and other high-profile cancers reported in recent years. With cancer as the second-leading cause of mortality worldwide, highlighting more than 9.6 million deaths annually, the need for advanced cancer detection is critical. Consequently, the development of next-generation diagnostics is enhancing accuracy and affordability, promoting early detection and improved patient outcomes amid a global healthcare landscape facing severe challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. Personalized medicine focuses on customizing treatments according to each patient's unique genetic makeup and specific characteristics, ensuring a more effective approach to cancer care. Advanced diagnostics tools are essential in this context, as they can pinpoint patients who are most likely to respond positively to tailored therapies. By facilitating the identification of suitable candidates for these individualized treatments, next generation cancer diagnostics not only enhance treatment efficacy but also drive innovation and growth within the healthcare sector.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges stemming from unclear reimbursement policies and the slow evolution of these frameworks. This ambiguity hinders the widespread adoption of innovative technologies, complicating the decision-making process for healthcare providers and patients regarding the justification of expenses linked to such diagnostic tests. Furthermore, reimbursement policies differ greatly across various countries, regions, and healthcare systems, leading to a fragmented landscape. In many instances, these policies are still under development, reflecting an absence of consensus on the appropriate reimbursement strategies for these advanced diagnostic solutions, which ultimately restricts their integration into clinical practice.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is increasingly shifting towards liquid biopsy tests, reflecting a significant trend in oncology diagnostics. These minimally invasive tests, which utilize blood, urine, and other bodily fluids to identify cancerous cells and biomarkers, are gaining traction due to their cost-effectiveness and ability to deliver rapid, reliable results. As healthcare providers seek more efficient diagnostic tools, the adoption of liquid biopsies is expected to grow, prompting substantial investments from biotech firms and research institutions. This evolving landscape is anticipated to reshape cancer detection and monitoring, driving innovation and improving patient outcomes in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2025-2032)

• Market Overview
• Products
  • Instruments
  • Kits & consumables
• Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• DNA microarrays
• Multiplexing
• Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast cancer
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Cervical cancer
• Liver cancer
• Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening and early detection
• Prognostics and monitoring
• Therapy selection
• Recurrence monitoring
• Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals & clinics
• Diagnostic laboratories
• Academic & research institutions
• Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2025-2032)

• North America (Product and Services, Technology, Cancer Type, Application, End Use)
  • US
  • Canada
• Europe (Product and Services, Technology, Cancer Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany/Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations